Journal article
A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY: COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
W Herring, IG Gould, L Ruiz, T Dort, Y Zhang, C Acosta, R Hyde, T Spelman, H Butzkueven
VALUE IN HEALTH | ELSEVIER SCIENCE INC | Published : 2018